Bio‐creep in non‐inferiority clinical trials

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Statistics in Medicine

• Publication date

  2010-11-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/sim.4053PMID 20809482
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Current issues in non‐inferiority trials

  2008cited by this paper
• Design and analysis of non‐inferiority mortality trials in oncology

  2004cited by this paper
• Alternatives for Discounting in the Analysis of Noninferiority Trials

  2004cited by this paper
• Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

  2004cited by this paper
• Assessing treatment efficacy in noninferiority trials.

  2003cited by this paper
• TACT method for non‐inferiority testing in active controlled trials

  2002cited by this paper
• Design and analysis of non‐inferiority mortality trials in oncology

  2002cited by this paper
• Some fundamental issues with non‐inferiority testing in active controlled trials

  2002cited by this paper
• Non‐inferiority trials: the ‘at least as good as’ criterion

  2002cited by this paper
• Non‐inferiority trials: design concepts and issues – the encounters of academic consultants in statistics

  2002cited by this paper
• Statistical Methods for Comparison to Placebo in Active-Control Trials

  2001cited by this paper
• Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo.

  2001cited by this paper
• Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

  2000cited by this paper
• Establishing equivalence by showing that a specified percentage of the effect of the active control over placebo is maintained.

  1999cited by this paper
• Self-designing clinical trials.

  1998cited by this paper

• Rank-based methods for assessing equivalence/non-inferiority with assay sensitivity in a three-arm trial with ordinal endpoints.

  2026cites this paper
• Understanding Noninferiority Trials: What Stroke Specialists Should Know

  2025cites this paper
• Phase 2/3 study evaluating safety, immunogenicity, and noninferiority of single booster dose of AVX/COVID-12 vaccine

  2025cites this paper
• Analyzing gaze and hand movement patterns in leader-follower interactions during a time-continuous cooperative manipulation task

  2025cites this paper
• Tuberculosis preventive therapy: scientific and ethical considerations for trials of ultra-short regimens.

  2025cites this paper
• Challenges for novel antiretroviral development in an era of widespread TLD availability.

  2024cites this paper
• Assessment of Noninferiority Margins in Cardiovascular Medicine Trials

  2024cites this paper
• Non-inferiority Study Design: Application to Clinical Trials.

  2024cites this paper
• Monkeypox, smallpox, FDA, and accelerated approval of vaccines – A regulatory perspective

  2023cites this paper
• Ensuring Superior Reporting of Radiation Therapy Noninferiority Trials: A Systematic Review

  2023cites this paper
• Study design approaches for future active-controlled HIV prevention trials

  2023cites this paper
• More than a decade since the latest CONSORT non-inferiority trials extension: do infectious diseases trials do enough?

  2023cites this paper
• Effectiveness of Standard Sequential Bilateral Repetitive Transcranial Magnetic Stimulation vs Bilateral Theta Burst Stimulation in Older Adults With Depression

  2022cites this paper
• THE REPORTING QUALITY OF NONINFERIORITY TRIALS USING INTRAVITREAL VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS

  2022cites this paper
• Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.

  2021cites this paper
• Framework for the evaluation of new tests for tuberculosis infection

  2021cites this paper
• Secondary Analysis of a Systematic Review: Are Antifungal Noninferiority Trials at Risk of Eroding Effectiveness Because of Biocreep?

  2021cites this paper
• Improved efficiency for cross-arm comparisons via platform designs.

  2021cites this paper
• Understanding the merits and drawbacks of noninferiority designs in cardiovascular medicine.

  2021cites this paper
• Placebo-To be or not to be? Are there really alternatives to placebo-controlled trials?

  2020cites this paper
• Business-as-Usual will not Deliver the COVID-19 Vaccines We Need

  2020cites this paper
• Novel Antibiotics May Be Noninferior but Are They Becoming Less Effective?: a Systematic Review

  2020cites this paper
• Methodological aspects of superiority, equivalence, and non-inferiority trials

  2020cites this paper
• Non-inferiority statistics and equivalence studies.

  2019cites this paper
• Designing noninferiority tuberculosis treatment trials: Identifying practical advantages for drug regimens with acceptable effectiveness

  2019cites this paper
• Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial.

  2019cites this paper
• Non-inferiority Trial Design in Drug Development: A Primer for Cardiovascular Healthcare Professionals

  2019cites this paper
• DOACs in Patients With Mitral Stenosis and Atrial Fibrillation: Time for a Randomized Clinical Trial.

  2019cites this paper
• Progress with drug-eluting stents - are we done?

  2019cites this paper
• A novel approach to sample size determination of clinical trials for rare diseases assuming symmetry

  2019cites this paper
• Comparative Effectiveness Research in Pediatric Respiratory Disease: Promise and Pitfalls

  2018cites this paper
• Detecting and accounting for violations of the constancy assumption in non-inferiority clinical trials

  2018cites this paper
• Do non-inferiority trials of reduced intensity therapies show reduced effects? A descriptive analysis

  2018cites this paper
• The Day After a Primary Endpoint.

  2018cites this paper
• Making 'null effects' informative: statistical techniques and inferential frameworks

  2018cites this paper
• New Regulatory Pathways for Antibacterial Drugs

  2018cites this paper
• Principles of Decision Making on the Prescription of Medicines. What else Do You Need to Know when Interpreting the Results of Clinical Trials?

  2018cites this paper
• Non-inferiority versus superiority drug claims: the (not so) subtle distinction

  2017cites this paper
• Optimizing Clinical Trials for Atopic Dermatitis in Children.

  2017cites this paper
• Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial

  2017cites this paper
• Regulatory Incentives for Antibiotic Drug Development: A Review of Recent Proposals.

  2016cites this paper
• Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation

  2016cites this paper
• Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections

  2016cites this paper
• Noninferiority Margin and Other Methodological Issues in Designing Noninferiority Trials: A Review

  2016cites this paper
• A Simulation Study Evaluating Bio-Creep Risk in Serial Noninferiority Clinical Trials for Preservation of Effect

  2015cites this paper
• The daisy chain effect in medical device approval: Progression to inferiority.

  2015cites this paper
• Group Sequential and Adaptive Designs for Three-Arm 'Gold Standard' Non-Inferiority Trials

  2014influential citation
• Choice of Non-Inferiority (NI) Margins Does Not Protect against Degradation of Treatment Effects on an Average – An Observational Study of Registered and Published NI Trials

  2014influential citation
• Systematic Review and Meta-Analysis of Antimicrobial Treatment Effect Estimation in Complicated Urinary Tract Infection

  2013cites this paper
• Should non-inferiority drug trials be banned altogether?

  2013cites this paper
• Assessing overall evidence from noninferiority trials with shared historical data

  2013cites this paper
• About half of the noninferiority trials tested superior treatments: a trial-register based study.

  2013cites this paper
• Systematic evaluation of non-inferiority and equivalence randomized trials of anti-infective drugs

  2013cites this paper
• Non-inferiority trials: methodological and regulatory challenges

  2012cites this paper
• 10 Years with ICH E10: Choice of Control Groups

  2011cites this paper
• Rationale for and Methods of Superiority, Noninferiority, or Equivalence Designs in Orthopaedic, Controlled Trials

  2011cites this paper
• Non-inferiority clinical trials: Practical issues and current regulatory perspective

  2011cites this paper
• Non-inferiority clinical trials: concepts and issues Estudos clínicos de não-inferioridade: fundamentos e controvérsias

  2010cites this paper